Diabetes mellitus is a type of metabolic disease that causes an insufficient secretionary amount of insulin or a dysfunction thereof, and is characterized by hyperglycemia (having a high blood glucose level). Hyperglycemia causes several symptoms and signs, and glucose to be excreted in urine. In addition, as time passes, vascular disorders and dysfunctions in nerves, kidneys, retinas, and the like are caused, which results in death.
Recently, due to a westernized diet, stress, lack of exercise, and the like, chronic and life-style related adult diseases such as arteriosclerosis, hypertension, and diabetes have been increasing.Also, only 73.4% of all the diabetic patients are aware of having the disease, and, particularly, approximately half (45.6%) of the young patients between 30 to 44 are not even aware of having the disease and thus run a high risk of being exposed to diabetic complications due to delayed treatment.
Up to now, various types of therapeutic agents for diabetes have been developed but a satisfactory treating method or medicine has not been developed yet.
The present technology portfolio is highly related toa new effective target protein and development of a therapeutic agent for diabetes or complications of diabetes
Why TENC1(Tensin like C1 domain containing phosphatase)? In type 2 diabetes,recently, a method of treating diabetes by increasing insulin signaling has been newly proposed. For this purpose, a method of suppressing expression of proteins such as PTP1B (protein tyrosine phosphatase 1B) that inhibits a function of an insulin receptor is under development. However, in type 2 diabetes, a problem in insulin signaling is generally caused by degradation of a function (a decrease in the amount of protein and tyrosine phosphorylation of IRS-1) of IRS-1 (insulin receptor substrate-1) rather than a functional degradation of the insulin receptor. Accordingly, a protein capable of regulating the function of IRS1 is important since it can be a target for treating diabetes and complications associated with diabetes.
Suppress IRS-1 degradability and/or dephosphorylation The Inhibitor of expression or activity of TENC1 suppressesdephosphorylationand degradation of IRS-1 caused by TENC1.
Possible to use as a treatment for diabetes and diabetic complications The inhibitor of expression or activity of TENC1 is able to prevent a glucose absorption decrease and muscular atrophy caused by a decrease of IRS-1.
Treatment for diabetes and its complications.
Diabetes Market It has been estimated that the world prevalenceof diabetes will more than double by 2030.Although incidence rates of type 1diabetes have remained fairly stable, the number of people diagnosed with type 2 diabeteshas been steadily growing.
The global type 2 diabetes market is set to almost double from $31.2 billion in 2015 to $58.7 billion by 2025, representing a compound annual growth rate of 6.5%. This growth will mainly occur across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, China, and India because of the growing prevalence of type 2 diabetes and obesity in these regions.
Diabetes ComplicationsMarket The diabetes complications space has high potential for changes and improvements as it becomes more diverse, with 30% of diabetic complication products in active development considered to be first-in-class.
The global diabetic nephropathy market was valued at USD 2,262.2 million in 2014 and is expected to grow at a CAGR of 5.6% from 2014 to 2020, to reach an expected value of USD 3,145.9 million in 2020.Increasing R&D investments in drug discovery and development and raising awareness about diabetes and kidney-related disorders are also driving the growth of the market.
The diabetic complications pipeline consists of 429 products that contain an array of targets not currently in use within the market. The increase in molecular target diversity signifies the high potential for changes and improvements in the diabetic complications market.
Highly effectiveness to Diabetes, and its complications.